DermAb.io is developing a clinical decision support system for prescribing personalized biologic therapies. Our non-invasive technology retrieves biomarkers painlessly from the skin’s surface. Our tool provides the predictive value for physicians to prescribe the most effective biological medication right away. The trial and error method applied today can add a cost of $8000 per patient, and extend the patient’s pain for months. The DermAb.io platform will significantly shorten the time to reach a proper treatment regimen, reducing costs and patients’ suffering.
DermAb.io was founded by two industry experts in monitoring skin biomarkers and their unheeded potential to mirror dermal and systemic chronic diseases. A proprietary prediction model for biological treatment of psoriasis has been developed and a patent is in process. DermAb.io is launching 3-5 centers for clinical trials of psoriatic patients treated with biologic drugs.
Blink is developing an independent energy and communication platform to power and connect smart ocular devices. BlinkIT™, our ergonomic smart patch situated on the eyelid, allows wireless charging and real-time data transfer between the ocular device and any smartphone.
That’s Blink Energy. www.blinkenrg.com
Improving Health Outcomes by Preventing and Detecting
Cognitive and Physiological Decline in Older Adults
CogMe aims to improve health outcomes by reducing cognitive and physiological decline in older adults, initially focusing on delirium in an inpatient setting. Using AI, CogMe provides a holistic solution that analyzes cognitive, physiological and activity indicators of the individual patient to predict, detect and intervene to prevent deterioration. Addressing a market of over $180 billion, the solution is an expert system that applies clinical guidelines and know-how, enhanced with machine and deep learning methodologies, to provide actionable data for personalized care plans.
Breaking the NGS Cost Barrier for Cancer Diagnostics
Breaking the NGS Cost Barrier for Cancer Diagnostics
Foresee Genomics has developed an innovative testing system for simultaneously identifying multiple cancer genomic markers, utilizing a revolutionary process that combines molecular biology and computational analysis.
Foresee Genomics elevates nanopore sequencing technology and will democratize NGS, making it available to any lab and anywhere.
GaitBetter promotes healthy aging by introducing a proprietary and clinically proven gait rehabilitation and falls prevention motor-cognitive training solution.
GaitBetter’s solution was shown to reduce the number of falls by 50% or more in research and in clinical use, with a lasting effect for months after training.
GaitBetter’s cognitive engagement add-on transforms any treadmill into a powerful motor-cognitive training device. The system is an ideal training in place solution for improving mobility for seniors and mobility impaired patients.
Biomarker platform for early detection in women’s health
Nevia bio is changing the women’s health space with its machine learning-based early detection platform of biomarkers from vaginal secretions, a previously untapped biofluid. Our platform is designed to decode data from biofluids, and to gain insights about physiological conditions.
Addressing the $10 billion ovarian health market, we are using our proprietary biomarker fingerprint to develop an early detection test for our first indication, ovarian cancer, with very promising clinical results.
PRECISION MEDICINE AI PLATFORM TARGETING COMPLEX POLYGENIC DISEASES, BASED ON GENOMIC AND CLINICAL DATA
Our vision is that the OpenDNA precision medicine AI platform will allow physicians to replace trial and error treatment strategies with precision care at reduced cost.
Our first clinical application is cardiometabolic syndrome, affecting about 1 billion patients worldwide, which includes diabetes, hypertension, elevated cholesterol and obesity, and leads to major cardiovascular, kidney and other complications. People with cardiometabolic syndrome are twice as likely to die from cardiovascular disease, resulting in about 5 million deaths annually, and an economic burden of up to $73 billion in the US alone and $286 billion globally.
OpenDNA is in the process of validating its cardiometabolic syndrome solution in pilot studies, and then will apply the technology to other conditions such as cancer, autoimmune and musculoskeletal disease.
PG Medical Systems is harnessing state of the art machine learning algorithms and telehealth tools to bring together patients, primary care physicians (PCPs) and pain experts. Our platform empowers PCPs with a pain medicine toolbox, allowing pain diagnosis and treatment to reach every patient at the right time and in the right place, bringing pain treatment and management to a new level.
We envision our system will bridge an evident gap in pain medicine practice and improve treatment outcomes, while lowering the risks of addiction to prescription drugs.
phenofAST is developing a fast and affordable bacterial antibiotic susceptibility test (AST). Current AST methods have a 2-3 day turnaround, resulting in 30% of patients receiving inappropriate antibiotic treatment, in an age of a growing antimicrobial resistance pandemic. phenofAST’s technology takes only 4 hours to test the susceptibility of bacteria to multiple antibiotic types, a key in preventing mistreatment-related health complications, shortening hospital stay, and reducing medical expenses.